Quality of life in lung cancer survivors treated with tyrosine-kinase inhibitors (TKI): results from the multi-centre cross-sectional German study LARIS.

Autor: Riccetti N; University Medical Center, Johannes Gutenberg University, Langenbeckstraße 1, 55131, Mainz, Germany. nriccetti@uni-mainz.de.; University Cancer Center Mainz, Langenbeckstraße 1, 55131, Mainz, Germany. nriccetti@uni-mainz.de.; Institute of Medical Biostatistics, Epidemiology, and Informatics (IMBEI), University Medical Center of the Johannes Gutenberg University, Obere Zahlbacher Straße 69, 55131, Mainz, Germany. nriccetti@uni-mainz.de., Blettner M; University Medical Center, Johannes Gutenberg University, Langenbeckstraße 1, 55131, Mainz, Germany.; Institute of Medical Biostatistics, Epidemiology, and Informatics (IMBEI), University Medical Center of the Johannes Gutenberg University, Obere Zahlbacher Straße 69, 55131, Mainz, Germany., Taylor K; University Medical Center, Johannes Gutenberg University, Langenbeckstraße 1, 55131, Mainz, Germany.; University Cancer Center Mainz, Langenbeckstraße 1, 55131, Mainz, Germany.; Institute of Medical Biostatistics, Epidemiology, and Informatics (IMBEI), University Medical Center of the Johannes Gutenberg University, Obere Zahlbacher Straße 69, 55131, Mainz, Germany., Wehler B; Universitätsklinikum Gießen Marburg GmbH Standort Gießen, Medizinische Klinik IV/V, Klinikstr. 33, 35392, Gießen, Germany., Gohrbandt B; Katholisches Klinikum Mainz, An der Goldgrube 11, 55131, Mainz, Germany., Nestle U; University Medical Center Freiburg, Albert-Ludwig-University, Hugstetter Str. 55, 79106, Freiburg im Breisgau, Germany.; Boehringer-Ingelheim, Binger Str. 173, 55216, Ingelheim am Rhein, Germany., Bals R; Department of Internal Medicine V, Saarland University Medical Center, Kirrberger Str. 100, 66421, Homburg, Germany., Stockinger M; University Medical Center, Johannes Gutenberg University, Langenbeckstraße 1, 55131, Mainz, Germany., Wehler T; Universitätsklinikum Gießen Marburg GmbH Standort Gießen, Medizinische Klinik IV/V, Klinikstr. 33, 35392, Gießen, Germany., Singer S; University Medical Center, Johannes Gutenberg University, Langenbeckstraße 1, 55131, Mainz, Germany.; University Cancer Center Mainz, Langenbeckstraße 1, 55131, Mainz, Germany.; Institute of Medical Biostatistics, Epidemiology, and Informatics (IMBEI), University Medical Center of the Johannes Gutenberg University, Obere Zahlbacher Straße 69, 55131, Mainz, Germany., Eichler M; University Medical Center, Johannes Gutenberg University, Langenbeckstraße 1, 55131, Mainz, Germany.; University Hospital Carl Gustav Carus, Fetscherstraße 74, 01307, Dresden, Germany.
Jazyk: angličtina
Zdroj: Journal of cancer research and clinical oncology [J Cancer Res Clin Oncol] 2022 Aug; Vol. 148 (8), pp. 1943-1953. Date of Electronic Publication: 2022 May 24.
DOI: 10.1007/s00432-022-03975-6
Abstrakt: Purpose: We aimed at exploring the quality of life (QOL) of lung cancer survivors with proven tyrosine-kinase receptor (RTK) genetic alterations and targeted tyrosine-kinase inhibitors (TKI) therapy, compared to lung cancer survivors with no-RTK alterations and no-TKI therapy.
Methods: Data were collected in a cross-sectional multi-centre study. Primary lung cancer survivors were asked about their socio-demographic and clinical information, QOL, symptom burden, and distress. QOL and symptom burden were assessed using the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire Core 30 (EORTC QLQ-C30), and distress with the Patient Health Questionnaire-4 (PHQ-4). Demographic and clinical characteristics were reported in absolute and relative frequencies, QOL, and symptom burden using mean scores. Differences in mean scores with relative 95% confidence intervals were used for comparison.
Results: Three groups of survivors were defined: group A with proven RTK alterations, TKI therapy at any time during therapy, and stage IV lung cancer at diagnosis (n = 49); group B: non-TKI therapy and stage IV lung cancer (n = 121); group C: non-TKI therapy and stage I-III lung cancer (n = 495). Survivors in group A reported lower QOL (mean score difference = -11.7 vs. group B) and symptom burden for dyspnoea (difference = -11.5 vs. group C), and higher symptom burden for appetite loss (difference =  + 11.4 vs. group C), diarrhoea and rash (differences =  + 25.6, + 19.6 and + 13.2, + 13.0, respectively, vs. both groups).
Conclusions: Our results suggest that the specific side effects of TKI therapy can impair QOL among lung cancer survivors. Therefore, specific focus towards the optimal management of these side effects should be considered.
(© 2022. The Author(s).)
Databáze: MEDLINE
Externí odkaz: